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Poster Session II S287decreases overall survival. Several risk factors for graft failure have
been reported, such as reduced intensity conditioning, HLA-mis-
match, T-cell depleted grafts etc. However, in the early post-trans-
plant period following myeloablative conditioning there is a lack of
tools for early detection of patients at risk for subsequent graft fail-
ure. For this purpose, we retrospectively evaluated all patients who
after myeloablative conditioning received peripheral blood cells
(PBSC) at our centre during 1995 to 2007 (n5 219). The indications
for transplantation were: AML (43%), ALL (23%), CML (17%),
myelodysplastic syndrome (6%), lymphoma (5%), metabolic disor-
ders (4%), and multiple myeloma (2%). Graft failure was defined
as absolute neutrophil count (ANC)\0.5  109/L or less than 5%
donor cell chimerism. Moreover, primary graft failure was set to
day 28 post-transplant, and patients who died prior to that day
were excluded from further analyses. Three patients experienced
graft failure within 100 days post-transplant (2 primary and 1 sec-
ondary graft failure), which means that the incidence of graft failure
was 1.4%. In univariate analysis, there was a tendency that the total
nucleated cell dose was associated with primary graft failure
(P5 0.06). In contrast, when analyzing risk factors for graft failure
within 100 days post-transplant the total nucleated cell dose seemed
to be unimportant (P5 0.17). Interestingly, in subanalyses the risk of
graft failure within 100 days post-transplant was markedly increased
in those patients who still had an ANC less than 0.2 109/L at day 16
post-transplant (OR5 30, P\0.01). In conclusion, we suggest that
in patients with less than 0.2  109/L in ANC 16 days post-trans-
plant one must consider interventions to avoid subsequent graft fail-
ure. For this purpose, strategies such as administration of
hematopoietic growth factors (e.g. G-CSF) or donor lymphocyte in-
fusions need further evaluation.348
IN-VIVO T-CELL DEPLETION USING THYMOGLOBULIN (THYMO) AL-
LOWS SUCCESSFUL ALLOGENEIC STEM CELL TRANSPLANTATION
(ALLO-SCT) FROM MISMATCHED, UNRELATED DONORS (MM-URD): PO-
TENTIAL INFLUENCE OF GRAFT SOURCE ON OUTCOME
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Historically, allo-SCT using MM-URD has been associated
with poor outcomes, due primarily to high rates of GVHD. De-
creasing the rate of GVHD, without increasing relapse, should
lead to better outcomes and wider use of this life-saving proce-
dure. Between 6/1/05 and 9/30/09, 88 patients (pts) received a first
allo-SCT from an unrelated adult volunteer donor at Mayo Clinic
Arizona/Phoenix Children’s Hospital. This report focuses on the
subset of 69 pts transplanted for malignancy who received at least
one dose of Thymo (dose range 2.5-10 mg/kg, dependent on de-
gree of HLA mismatch) as part of their GVHD prophylactic reg-
imen (19 excluded, 9 with non-malignant disease, 10 who did not
receive Thymo due to MD preference). Forty-two pts were HLA-
identical (10/10) with their unrelated donor by high resolution
typing, while 27 were mismatched at one or more loci as follows:
1 allele mismatch (7); 1 antigen (Ag) mismatch (11); 2 allele mis-
match (2); 1 Ag and 1 allele mismatch (5); and 2 Ag mismatch (2).
The median age was 37 (0.5-75). Conditioning was ablative in 48,
reduced intensity in 21; graft source was PBSC in 47, marrow in
22. In addition to Thymo, all pts received a calcineurin inhibitor
(or sirolimus) plus methotrexate or MMF for GVHD prophylaxis.
The outcomes are shown in the Table. The estimated 2-yr overall
survival (OS) did not differ between the matched (61.1%) and mis-
matched pts (60.5%). The rates of aGVHD grades II-IV (48.6%
matched vs. 39.9% mismatched) and relapse (28.6% matched vs.
17.5% mismatched) also were not significantly different. Pts who
received mismatched marrow grafts had relatively poor outcomes
(2 yr OS 21.9%) due to increased relapse and higher than expected
NRM, which did not appear to be explained by higher disease risk.
By design, these pts received relatively high doses of Thymo (7.5-
10 mg/kg), and such high doses may have led to excessive T-cell
depletion of marrow grafts, abrogating the graft vs. malignancyeffect and leading to increased infectious mortality. In contrast,
pts receiving mismatched PBSC grafts (who received similar doses
of Thymo), had good outcomes (2 yr OS 91.5%) and low relapse
rates (2 yr rel 0%). We conclude that 1) using PBSC as graft
source and in vivo T-cell depletion, mismatched unrelated SCT
can be safely performed with excellent outcomes in adult and pe-
diatric pts with hematologic malignancy; and 2) modification of
the Thymo dose will be necessary to achieve similar success using
marrow grafts.
Outcomes by Match Grade and Graft Type
2 Yr 2 Yr aGVHD aGVHD
Match Grade Graft N OS Rel II-IV III-IVMatched Either 42 61.1% 28.6% 48.6% 8.3%
Matched PBSC 30 57.3% 30.4% 46.2% 8.1%
Matched Marrow 12 68.2% 25.4% 53.9% 8.8%Mismatched Either 27 60.5% 17.5% 39.9% 14.6%
Mismatched PBSC 17 91.5% 0.0% 41.8% 16.3%
Mismatched Marrow 10 21.9% 50.5% 37.1% 12.2%349
PERIPHERAL BLOOD CHIMERISM CAN REPLACE MARROW CHIMERISM
ANALYSES FOLLOWING ADULT ALLOGENEIC STEM CELL TRANSPLANT
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Chimerism defines the amount of donor versus recipient hema-
topoiesis following allogeneic stem cell transplant (SCT). PCR-
based analyses of short tandem repeats (STRs) are commonly
used and are accurate and applicable to allogeneic transplant recip-
ients. These analyses are performed on peripheral blood and mar-
row aspirates, but it is not known if it is necessary to analyze both.
We performed a retrospective analysis of 42 consecutive adult allo-
geneic SCT recipients at our institution with available chimerism
studies. PCR and capillary electropheresis of microsatellite loci
were performed at 30, 60, and 90 days after SCT on both unfrac-
tionated blood and unfractionated marrow aspirate. Full donor chi-
merism (FDC) was defined as 95% or greater donor chimerism.
PCR analyses of STRs for chimerism performed on unfractionated
blood did not differ from results obtained on unfractionated mar-
row aspirate at 30, 60, or 90 days post transplant (P\0.0001). Pe-
ripheral blood PCR-based chimerism analyses provide similar
information as marrow aspirate analyses. Using peripheral blood
alone saves the expense of an additional analysis on marrow aspirate
and prevents an uncomfortable procedure. These findings provide
unique results suggesting larger studies in the adult population
are needed to further delineate the role of chimerism analyses
following allogeneic SCT.350
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Introduction: Allogeneic hematopoietic stem cell transplantation
(HSCT) is a curative treatment option for an expanding spectrum
of patients (pts) with a greater variety of diseases and graft sources,
cytoreductive regimens, cellular therapies, and supportive care.
S288 Poster Session IIT cell depletion (TCD) has successfully reduced the risk of graft ver-
sus host disease (GVHD) but concerns about relapse and infections
have limited its application.
Methods: Between 7/2001 and 12/2005, 35 pts underwent TCD
HSCTs as treatment for hematologic malignancies using HLA-
matched (HLA-M)(20 pairs) or mismatched (-MM)(15 pairs) unre-
lated donors. The conditioning regimen, hyperfractionated total
body irradiation (1375 cGy), fludarabine (25 mg/m2) x 5d, and thio-
tepa (5 mg/kg) and antithymocyte globulin 2d, was designed to re-
duce toxicity, while preserving immunosuppression for engraftment.
Donors were $8 of 10 HLA matched by DNA SSOP analyses. Pts
received TCD-peripheral blood stem cells (PBSC) (n5 29) or
TCD-bonemarrow (BM) (n5 6). PBSCs were CD34+ selected (Iso-
lex 300i columns) and BMs agglutinated by soybean lectin, after
which both underwent sheep erythrocyte-rosette sedimentation.
The median age was 40.5yrs (18-63). Diseases included AML (stan-
dard or high risk) and ALL (high risk) CR1, AMLCR2, ALL$CR2,
acute biphenotypic leukemia, CML-CP,MDS, T-PLL.Median fol-
lowup is 52 mos (37-83).
Results: All evaluable pts engrafted neutrophils, and 31/34 evalu-
able pts engrafted platelets. The 100d non-relapse mortality was
20% with infection causing .50% of deaths. 9% developed only
acute GVHD grade II-III and 29% chronic GVHD, with no signif-
icant difference between HLA-M and -MM subsets. Estimated 4 yr
DFS and OS is 56% and 59%, with DFS of 75% for pts with stan-
dard risk and 41% for high risk disease. Two high risk disease pts
relapsed at 31 and 38 mos. Infectious deaths were: 2 viral, 1 toxo-
plasma, 1 fungal, 2 bacterial. Median time to achieve normal
CD3 +CD8+ and CD3 +CD4+ counts were approximately 4-6
and 6-9 mos posttransplantation, respectively. Only 4 pts, who
had been treated with steroids, had CD3 +CD4+ counts \100
cells/ul by 1 yr. 50% of patients reached a normal PHA proliferative
response in vitro within 1 yr.
Conclusions: Outcomes with this cytoreductive regimen followed
by TCD PBSC or BM are similar to those reported for TCD
matched related donor, and for unmodified transplants but with
a much lower incidence of GVHD. Relapse rates, with followup of
.3 yrs, remain remarkably low.351
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The incidence of liver related morbidity and mortality after al-
logeneic hematopoietic cell transplantation (Allo-HCT) in patients
positive for hepatitis B surface antigen (HBsAg +) may increase,
but it has been not well analysed. The aim of this study is to de-
termine the frequency of HBV reactivation and to evaluate the ef-
fect of HBV reactivation on early transplant-related complications
in a retrospective single center cohort. We detected HbsAg+ 23
patients (3.8%) who underwent allo-HCT (n5 680) within 10
years. Median age was 33 years. Twenty-two were male and one
female. Liver function tests were normal and HBV-DNA negative
in 20 patients prior to the transplant. Myeloablative (n5 20) or
fludarabine based-reduced intensity conditioning regimen (n5 3)
were used. Lamivudin prophylaxis was initiated 100 mg p.o o.d.
in 14 patients with conditioning regimen and was continued until
6-12 months after the cessation of immunosuppresion at post-
transplant period. Six patients had HBsAg+ donor, 5 seropositive
(antiHBs with antiHBc IgG, 3 antiHBs alone and 6 were negative
HBV naive. We could not obtain enough data about HBV serol-
ogy of 3 donors. HBV reactivation was observed in 7 patients after
median 4.5 months (range, 0.87-23.5) after the Allo-HCT. All the
patients with HBV reactivation had received myeloablative condi-
tioning. There was an increase of serum ALT (2.5UNL- 54
UNL) level with positivity for HBV-DNA during reactivation.
The reactivation was observed only in one patient during lamivu-
dine prophylaxis 7.6% vs 60%. p5 0.012) while one patient expe-
rienced a reactivation in 2 months after cessation of prophylaxis.Two patients with HBV reactivation had donors positive for
HBsAg. Lamivudin treatment was given in 5 patients after reacti-
vation. Lamivudin resistance was observed in two patients, who re-
ceived second line antiviral treatment. One of those patients died
of fulminant hepatic failure. The incidences of acute or chronic
liver graft versus host disease were not affected from HBV reacti-
vation. The reactivation HBV is one of the most undesired com-
plications of chemo/immunosuppressive treatment in HBsAg
positive Allo-HCT recipients. The prophylaxis with lamivudine
could decrease the frequency of HBV reactivation. But the devel-
opment of the lamivudine resistance is another problem in some
patients requiring long-term treatment. In conclusion, our study
has shown that HBsAg+ recipients did not have a strict limitation
for allo-HCT.352
QUANTITATIVE ANALYSIS OF LINEAGE-SPECIFIC CHIMERISM FOR MON-
ITORING POST-HAEMATOPOIETIC STEM CELL TRANSPLANTATION EN-
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Haematopoietic stem cell transplantation (HSCT) is an estab-
lished treatment for various hematological disorders. The moni-
toring of post-transplant engraftment has become a routine
diagnostic assay in the clinical laboratory. PCR-based methodolo-
gies utilizing STR analysis and commercial multiplex assays are
frequently used. However, these commercial kits were originally
formulated for forensic applications and do not completely fulfill
the needs of diagnostic chimerism testing, especially for non-mye-
loablative bone marrow transplants, in which treatment depends
on the status of lineage-specific chimerism. We utilize the Beck-
man-Coulter GenomeLab Human STR Primer Set (Fullerton,
CA) in our clinical laboratory. This kit consists of twelve STR
markers in a single multiplex PCR reaction and has proven highly
informative, sensitive and rapid in routine clinical testing. For use
with this kit, DNA is extracted from peripheral blood, bone mar-
row, and/or CD3/CD33/CD56-enriched fractions sorted on the
BD Biosciences FACSAria Cell Sorting System (San Jose, CA)
and extracted with the Qiagen Blood Kit or Qiagen Micro Kit
(Valencia, CA). 60 blood samples from multiple College of Amer-
ican Pathologists (CAP) proficiency panels were evaluated. These
panels are challenges proctored by CAP and participated in by
up to 80 US labs 3 times per year. Correlation of results were ex-
cellent (r25 0.99). This method has been in use by our laboratory
since the summer of 2005 with approximately 4500 patient sample
studies. In our experience no pre-transplant/donor combination
has yielded a non-informative result, even between siblings. We
have found the STR-based method to be a rapid, specific, sensi-
tive, and cost-effective diagnostic assay for monitoring donor
cell engraftment after HSCT transplantation, making it a respon-
sive tool for rapid clinical decision making. The assay is stream-
lined to provide rapid turn-around-time and requires a minute
amount of DNA making it an excellent tool for patients with
low white blood cell counts. This methodology is also suitable
for detection of maternal cell contamination and for verifying pa-
thology specimen identification.353
CONFIRMATION OF UNRELATED CORD BLOOD TRANSPLANT AS A
TREATMENT STRATEGY FOR SEVERE APLASTIC ANEMIA
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The St. Louis Cord Blood Bank (SLCBB) serves to collect,
process, cryopreserve, and distribute umbilical cord blood for hu-
man transplantation. To date, nearly 1,600 units have been dis-
tributed globally for the treatment of more than 70 diseases
